Skip to main content
Premium Trial:

Request an Annual Quote

FDA Chief: Action Plans for Shortening Approvals, Sharing Pharmaco Data, Are Coming

BOSTON, Aug. 12 (GenomeWeb News) - FDA Commissioner Mark McClellan told drug industry executives this morning that the agency will soon release an action plan aimed at bringing together the best biomedicine with risk management and economic science to "give the public bang for the buck in the areas we regulate." McClellan's remarks came during the keynote address at IBC's 8th Annual Drug Discovery Technology Congress, which has attracted some 6,000 pharma sector people to Boston, Mass.- the state that McClellan said is responsible for 80 percent of the discoveries in the current new drug pipeline.

 

McClellan said the agency wants to "do our part to help developers" submit new drug applications that contain the information they need to get approved quickly. He emphasized a new focus on "improving the drug development process to make it less risky, more certain, and less time consuming." By 2005 he said he aims to reduce to 30 days the average total review time for priority applications. For standard applications McClellan said companies should be able to get approval within two months.

 

To achieve this, McClellan, who was appointed last year, will foster earlier communications between drug developers and the FDA in order to give companies feedback that will help reduce review times. And, though he left out specifics, McClellan said he would set up programs to enable pharma companies and the FDA to share data gleaned from pharmacogenomics technologies such as microarrays.

 

The picture McClellan painted of the modern drug development process was a discouraging one.  Delayed FDA review times are to blame for only 10 percent of the time, start to finish, that it takes to get a drug to market, he said. In 2002 FDA approved 21 new molecular entities - less than half the number approved in 1996. New device approvals were also down, he said, attributing both numbers to an overall decline in applications. In the period since 1995, pharma research spending has doubled, he said, citing the current annual worldwide level at $54 billion.

 

With nods to developments in genomics, proteomics, systems biology, biomarkers, and information technology, McClellan said he is seeing more novel drugs and more genomics-based drugs entering late stage development, but that the industry needs to speed things up. "We can't wait 10 to 15 years for the payoff." He hopes that FDA's new action plan, to be unveiled "shortly," will offer guidance that can help industry increase value, avoid delays, and trim costs.

 

 

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.